Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;20(4):177-183.
doi: 10.5114/pm.2021.110935. Epub 2021 Nov 24.

The effect of low-dose combined hormone therapy (oestradiol and norethindrone acetate) on serum C-reactive protein levels and life quality in natural menopause women

Servin Gocer  1 , Suleyman Guven  2 , Hidayet Sal  2 , Emine Seda Guvendag Guven  2
Affiliations

The effect of low-dose combined hormone therapy (oestradiol and norethindrone acetate) on serum C-reactive protein levels and life quality in natural menopause women

Servin Gocer et al. Prz Menopauzalny. 2021 Dec.

Abstract

Introduction: To assess the effect of low-dose combined oestradiol and norethindrone acetate hormone therapy (HT) on serum C-reactive protein (CRP) levels and life quality in natural menopause women.

Material and methods: Forty-five natural menopause women admitted to the clinic during a 1-year period and diagnosed as menopause, who planned to have HT for menopausal symptoms, were enrolled in this prospective study. The serum CRP levels were measured, and vasomotor symptoms scores were graded according to the Blatt-Kupperman menopause index, and life quality scores according to the Menopause-Specific Quality of Life Questionnaire (MENQOL) were recorded before and after (3 months later) hormone therapy.

Results: The Blatt-Kupperman menopause index and MENQOL scores were significantly decreased after 3 months of low-dose treatment. No significant difference was found between white blood cell counts and serum CRP levels before and after 3 months of hormone therapy.

Conclusions: Considering all HT types and biochemical effects, low-dose HT, which had positive results in terms of quality of life, was a safe treatment and could be preferred to conventional-dose preparations in cases without contraindications. Low-dose combined HT containing oestradiol and norethindrone acetate did not alter the serum CRP level in postmenopausal cases.

Keywords: Blatt-Kupperman index; CRP; Menopause-Specific Quality of Life Questionnaire (MENQOL); norethindrone acetate; oestradiol.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Kronenberg F. Hot flashes: epidemiology and physiologya. Ann N Y Acad Sci 1990; 592: 52-86. - PubMed
    1. Genazzani A, Nicolucci A, Campagnoli C, et al. . Assessment of the QoL in Italian menopausal women: comparison between HRT users and non-users. Maturitas 2002; 42: 267-280. - PubMed
    1. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992; 15: 151-158. - PubMed
    1. Utian WH, Schiff I. NAMS-gallup survey on women’s knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 2018; 25: 1172-1179. - PubMed
    1. Hemelaar M, Kenemans P, Schalkwijk C, Braat D, van der Mooren M. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women. Hum Reprod 2006; 21: 1635-1642. - PubMed